CMP: 265

Ipca Laboratories Limited operates a pharmaceutical company, which distributes products to over 75 countries worldwide. The Group's products include finished dosage forms, drug delivery systems, bulk drugs and intermediates.

Ipca Laboratories is a good bet in mid-cap pharma space. Its currently trading at a P/E of little less than 13 with dividend yields well over 1% in the last 12 months. Manageable liability. Revenues have risen steadily from 917 Crores to 1881 Crores in the last 5 years. Profits have risen from 122 Crores to 255 Crores in the same period. NPM has marginally improved from 13% towards 14% over 5 years. Buy and hold for long term gains.